MSV-nab-PTX

MSV-nab-PTX (multistage vector-nanoparticle albumin-bound paclitaxel) is an investigational drug delivery system designed to enhance the therapeutic efficacy of albumin-bound paclitaxel (nab-paclitaxel) in hypovascularized metastatic lesions, particularly breast and lung cancer liver metastases, as well as pancreatic ductal adenocarcinoma. Developed by the Houston Methodist Research Institute in collaboration with the University of Louisville, the system consists of nab-paclitaxel loaded into porous silicon multistage nanovectors (MSV). This formulation shifts drug transport from endothelial cells toward tumor-associated macrophages (TAMs) in the liver, which engulf the MSV particles and act as a drug depot, slowly releasing paclitaxel in the tumor microenvironment. Additionally, the MSV particles release zinc ions (Zn2+) that act as histone deacetylase (HDAC) inhibitors, suppressing HDAC activity and triggering epigenetic activation of pro-inflammatory genes to facilitate the polarization of TAMs from the immunosuppressive M2 phenotype to the anti-tumorigenic M1 phenotype. MSV-nab-PTX has demonstrated significant efficacy in preclinical models, prolonging survival and reducing tumor growth compared to standard nab-paclitaxel.

Other names

MSV-nAb-PTXMSV-nAb-paclitaxelmultistage vector-albumin-bound paclitaxelmultistage vector-nanoparticle albumin-bound paclitaxel